US Patent 7419663 Treatment of complement-associated disorders
Patent 7419663 was granted and assigned to Genentech on September, 2008 by the United States Patent and Trademark Office.
All edits
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Infobox (+10 properties)
Infobox
Patent Inventor Names
Audrey Goddard0
Austin L. Gurney0
Avi Ashkenazi0
Daniel Tumas0
Karim Yussef Helmy0
Kenneth James Katschke, Jr.0
Mary A. Napier0
Menno Van Lookeren0
Sherman Fong0
William I. Wood0
Edits on 14 Sep, 2023
Golden AI
Edits made to:
Article (+170 characters)
Article
Patent abstract
The present invention concerns a recently discovered macrophage specific receptor, STIgMA, and its use in the treatment of complement-associated disorders.
Edits on 15 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07419663 Treatment of complement-associated disorders US Patent 7419663 Treatment of complement-associated disorders
Infobox
Patent Number
074196630
Patent Number
74196630
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
074196630
Date of Patent
September 2, 2008
0Patent Application Number
109642630
Date Filed
October 12, 2004
0Official Website
Patent Primary Examiner
Edits on 14 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 1 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07419663 Treatment of complement-associated disorders
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07419663
Date of patent
September 2, 2008
Patent application number
10964263
Date Filed
October 12, 2004
Patent primary examiner
Find more entities like US Patent 7419663 Treatment of complement-associated disorders
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
